Group items tagged

The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline. This project is part of the NIH initiative to establish a public-private partnership to address the opioid crisis via more effective and safe ways to prevent and treat opioid use disorders and overdose. https://www.nih.gov/opioid-crisis

The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat Substance Use Disorders (SUDs) move through the drug development process. Both the project period and budget of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding. Project aims can range from the development of a new molecular entity to the expansion of an existing medication's clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process. It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs.

This Funding Opportunity Announcement (FOA) invites grant applications from institutions/organizations that propose to build research infrastructure to promote external collaboration with the medical rehabilitation community. The aim of this FOA is to create a national network of research cores that provide access to collateral expertise in biomedical, behavioral, engineering, and/or psychosocial fields that is particularly relevant to medical rehabilitation research. We are particularly interested in supporting infrastructure programs in clinical trial design, engineering and the environment, individualized medical rehabilitation and dynamic reassessment, and applied behavioral supports for rehabilitation research and healthy outcomes. However, other areas of expertise may be proposed provided they offer unique research opportunities and have potential for promoting medical rehabilitation research and improving outcomes for people with disabilities. In response to this FOA, applicants should propose a program of research resources and collaborative opportunities in a specific research domain. This may be accomplished through a workshops, written material, and websites, consultations, collaborations, and pilot funding. In addition, the research core may support activities within the grantee institution related to technique development, adaptation, and validation. To accomplish the aims of the FOA, applicants may propose collaborations to other institutional sites, provided that they cover the appropriate administrative and logistical issues.

Applications to the Fiscal Year 2017 (FY17) Psychological Health and Traumatic Brain Injury Research Program (PH/TBIRP) in the area of Applied Behavior Analysis for Autism are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The U.S. Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP) provides PH/TBIRP execution management support aligned with specific DHP research program areas. The execution management agent for this Program Announcement is the CDMRP, with strategic oversight from the DHA. The PH/TBIRP was established by Congress in FY07 in response to the devastating impact of traumatic brain injury (TBI) and psychological health (PH) issues, including post-traumatic stress disorder, on our deployed Service members in Iraq and Afghanistan. The PH/TBIRP mission is to establish, fund, and integrate both individual and multi-agency research efforts that will lead to improved prevention, detection, and treatment of PH issues and TBI. The vision of the PH/TBIRP is to prevent, mitigate, and treat the effects of traumatic stress and TBI on function, wellness, and overall quality of life for Service members as well as their caregivers and families. The DHA leverages PH/TBIRP funding to complement DHP core research and development funding assigned to study PH and TBI.

This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues are encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.

The Communities Building Healthier Environments for a Stronger Nation Initiative ('Communities Initiative') intends to demonstrate the effectiveness of community-based networks in improving health outcomes among racial and ethnic minority and/or other disadvantaged populations. This program seeks to improve health outcomes through the establishment of integrated networks that collaboratively employ evidence-based disease management and preventive health activities; build the capacity of communities to address social determinants and barriers to healthcare access; and increase access to and utilization of preventive health care, medical treatment, and supportive services. The Communities Initiative specifically targets the unmet healthcare and supportive service needs of racial and ethnic minority populations at highest risk for poorer health outcomes. Health services provided under the Communities Initiative will not be denied to any person based on race, color, or national origin. Populations at highest risk include, but are not limited to, individuals who are newly diagnosed and lack a medical home; individuals who experience difficulty in adhering to a prescribed medical treatment plan; individuals with a chronic disease that is not well managed; and individuals that are unstably housed. Specific health areas to be addressed by the Communities Initiative include asthma, cardiovascular disease, diabetes, HIV/AIDS, Hepatitis B or C, obesity/overweight, and mental disorders. Community health programs are required to address social determinants of health, and improve coordination of health, social, and supportive services to significantly improve health outcomes among minority and/or disadvantaged communities. Applicants must choose two but no more than three chronic conditions

Through the program, a single grant of up to $20,000 will be awarded in support of the practice/education of or research by an early-career psychologist that explores the connection between mental and physical health, with a focus on work/research that contributes to public health. Examples of initiatives eligible for support include but are not limited o: research-based programs that teach medical doctors counseling skills; research-based programs focused on the effect of behavior on health; and research-based programs that explore psychologists' role in medical settings for the benefit of patients. Priority will be given to psychologists working in medical schools.

With support from the Gordon and Betty Moore Foundation, researchers from the Johns Hopkins School of Nursing (JHSON), Duke University Margolis Center for Health Policy, University of Michigan Medical School and the Society for Medical Decision Making (SMDM) have partnered to catalyze innovative COVID-19 decision models for rapid uptake and impact. The COVID Decision Modeling Initiative (CDMI) will support the development of decision models to inform the urgent needs of decision makers responding to the Covid-19 pandemic. CDMI has several specific goals to facilitate responsive decision modeling research: Determine key priorities and critical questions where decision modeling can support better decisions and outcomes during the COVID-19 pandemic Implement grant making program to fund 6-10 projects with rapid impact potential Leverage Society for Medical Decision Making (SMDM) repository of models and network of decision modelers addressing COVID-19 To optimize success of decision modeling projects funded for rapid impact, the research team will coordinate efforts from their institutions along with the SMDM COVID-19 Modeling Special Committee to provide connectivity between decision makers and decision modelers and disseminate the combined CDMI results to the public at large. Johns Hopkins University will administer 6-10 agreements to recipients for decision modeling projects with anticipated impact within 4-6 months from start date.

Competitive applications will focus on studies that achieve one or more of the following goals: - Characterize disease progression for people with Parkinson's - Evaluate the utility of different instruments and/or instrument sub-items in measuring burden of disease, especially in individuals within the first two (2) years of Parkinson's diagnosis - Identify the role of pharmacological, medical device and/or non-medical interventions on managing Parkinson's symptoms and long-term health outcomes - Predict the future health status of participants without Parkinson's based on disease risk variables and model their likelihood of developing Parkinson's - Determine elements of disease experience that drive patient preference and risk tolerance - Explore the factors that affect volunteer compliance and completeness of participation in an online study - Determine how economic factors, patient-physician communication and lifestyle factors influence medical treatment and long-term health outcomes in people with Parkinson's - Analyst's choice: Researchers can submit their own analysis topics based on available Fox Insight data especially as it relates to longitudinal analyses

A cancer survivor is a person diagnosed with cancer, from the time of diagnosis throughout the person’s lifespan. As of 2008, nearly 12 million cancer survivors were living in the United States; this number is expected to increase to 18 million in 2020. Cancer survivors have long-term adverse physical and psychosocial effects from their diagnosis and treatment, and have a greater risk for additional cancer diagnoses compared with persons without a cancer history. Cancer survivors commonly report negative behavioral, medical, and health care access issues that may contribute to poor long-term medical and psychosocial outcomes. An analysis of over 45,000 U.S. cancer survivors showed that: 1) 15% of cancer survivors continue to use tobacco; 2) 20-25% do not receive recommended cancer screenings; 3) 31% do not engage in any leisure time physical activity; 4) 40 to 50% do not receive flu or pneumonia vaccines; 5) 60% do not have a summary of their cancer treatment; and 6) 25% do not have any instructions (written or oral) for their treatment or follow-up care . CDC’s National Comprehensive Cancer Control Program (NCCCP) supports collaborative cancer control and prevention efforts in all states, the District of Columbia, tribal organizations, territories, and Pacific Island jurisdictions to address the cancer burden in their jurisdictions. In 2010, NCCCP developed six priorities areas of focus for the greatest public health impact; one of the six priorities is to address the public health needs of cancer survivors. The purpose of this FOA is to implement a broad set of evidence-based survivorship strategies in a subset of NCCCP grantees that will have the short-term results of increasing knowledge of cancer survivor needs, increasing survivor knowledge of treatment and follow-up care, and increasing provider knowledge of guidelines pertaining to treatment of cancer. Intermediate outcomes include the development of best practices in survivorship among NCCCP gra

The Substance Abuse andMental Health Services Administration (SAMHSA), Center for Substance AbuseTreatment (CSAT), isaccepting applications for fiscal year (FY) 2019 Provider's Clinical SupportSystem - Universities (Short Title: PCSS-Universities) grants. The purpose of this program is toexpand/enhance access to medication-assisted treatment (MAT) services forpersons with an opioid use disorder (OUD) seeking or receiving MAT throughensuring the education and training of students in the medical, physicianassistant and nurse practitioner fields. This program's focus is to ensure students fulfill the trainingrequirements needed to obtain a DATA waiver to prescribe MAT in office-basedsettings. The desired outcomes include: 1) an increase in the number of individuals completing the trainingrequirements for the DATA waiver, 2) an increase the number of individuals witha DATA waiver, and 3) an ultimate increase in those prescribing.

The MBRP Clinical Translational Research Award (CTRA) is intended to support clinical research projects that are likely to have a major impact on therapy by applying promising and well-founded laboratory, preclinical, or clinical research findings to the care of the burn-injured patient. Burns have comprised some 5%-20% of the casualties sustained in post-World War II conflicts.1 Potential future conflicts may cause a rise in the number of burn injuries sustained by Service members and the general public should those conflicts occur in rural areas, austere combat zones, and in mass casualty events, whereby medical resources are limited and/or access to medical care is delayed for hours, days, or weeks. In order to prepare the military and the Nation for such potential future conflicts, the FY19/20 MBRP is soliciting research to provide burn care solutions closer to the point of injury for the pre-hospital setting and for a prolonged field care scenario. The North Atlantic Treaty Organization (NATO) defines prolonged field care (PFC) as field trauma care extended beyond doctrinal timelines until the patient can be transported from the point of injury to an appropriate level of care. PFC has been identified as a high priority capability gap across the Army and other Services. Additional information regarding PFC can be found in the following articles, Prolonged Field Care: Beyond the 'Golden Hour'2 and Prolonged Field Care the New Normal says Army, MRMC Brass.3 Although encouraged, applications submitted to the FY19/20 MBRP CTRA are not required to address PFC. However, the proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

Allergan's Alliance Advocacy Department considers support requests for therapeutically aligned non-profit  organizations in the following four categories:  Awareness & Advocacy:  Support for development of educational materials and resources geared toward healthcare providers, patients, caregivers, policy decision makers, and the public at large that are designed to expand disease-state awareness and increase knowledge of treatment options and access to appropriate care Corporate Membership: Membership to a healthcare provider association, patient advocacy group, or policy coalition that offers an industry advisory council or forum   Fund-raiser: National organization gala, walk, or other fundraising event   Non-Medical Education Meeting:  Support for non-medical education programs/events for healthcare providers, patients, caregivers, policy decision makers, and the public at large that are designed to expand disease-state awareness and increase knowledge of treatment options and access to appropriate care

HIV+ alcohol users remain at high risk for medication non-adherence and rapid disease progression, medication toxicities, organ failure, and poor viremic control, leading to increased risk of transmission and premature death. Recent advances in technology and biomedical science (e.g., new pharmacological agents, alcohol and inflammation biomarkers, internet and mobile technology) open new opportunities for strengthening the quality of HIV/alcohol-related implementation research through utilization of novel technology and biomarkers. This initiative seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Multiple factors need to be investigated, including potentially important patient and provider characteristics, and the organizational, financial, and structural factors that facilitate or inhibit the delivery of evidence-based services for HIV+ individuals with a range of severity of alcohol use problems. The overall goal is to inform clinical decision-making to implement effective interventions that will improve prevention, care, and outcomes across the continuum of HIV and alcohol problem severity and patterns of alcohol use. This solicitation is divided into two major topics. An application may choose to address one or both. These topics include: 1) comparative effectiveness research focused on understanding factors related to early detection, patient engagement and retention in appropriate alcohol and HIV care, and achieving and maintaining optimal treatment responses in diverse settings, and 2) modeling and testing alternative implementation approaches to improve uptake and scaling-up of effective interventions and reduce HIV disease transmission and progression.

NIFA requests applications for the Mental Health Research Project (MHRP) for the fiscal year FY 2017 to support the Air Force Medical Operations Agency (AFMOA) MHRP in promoting the psychological health and well being for Airmen and there families through staff development, consultation, program and resource development; program evaluation, and data tracking.The primary objective for this project is to assess, develop, and evaluate programming to treat and prevent mental health problems to support the Mental Health Division of the Air Force Medical Operations Agency (AFMOA).This work also supports the mission of the DoD-USDA Partnership for Military Families Memorandum of Understanding (MOU) signed in 2010 by NIFA and DoD senior leadership. The goal of the MOU is "…to enhance federal interagency coordination and build capacity for partnerships and collaboration among the agencies and across public and private sectors to sustain programs and services for military service members and their families."

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to evaluate the cumulative and progressive effects on brain structure and cognitive/behavioral function of combined HIV infection and alcohol abuse. This project has recruited and longitudinally tracked a large cohort of individuals with HIV infection, or alcohol abuse, or the comorbid condition. As members of this cohort are growing older and living well longer due to antiretroviral medications, this project is well suited to address several questions of current interest in the HIV-AIDS research community. These questions include the effects of coinfection with the Hepatitis C virus, the involvement of peripheral neuropathy as a factor in frailty, potential neurotoxic effects of antiretroviral medications, and interactive effects with advancing age on sensory and motor functioning.

The Autism Science Foundation is inviting applications for its Pre- and Postdoctoral Training Awards from graduate students, medical students, and postdoctoral fellows interested in pursuing careers in basic and clinical research relevant to autism spectrum disorders. The proposed training must be scientifically linked to autism and may be broadened to include training in a closely related area of scientific research, including but not limited to human behavior across the lifespan (language, learning, behavior, communication, social function, motor skills & planning, epilepsy, sleep, repetitive disorders), neurobiology (anatomy, development, neuroimaging), pharmacology, neuropathology, genetics, epigenetics, genomics, epigenomics, immunology, molecular and cellular mechanisms, studies employing model organisms and systems, and studies of treatment and service delivery. Special consideration will be given to projects focused on gender issues in autism. This includes studies examining the female protective effect, neurobiological and neuroanatomical examination of the female autism brain, diagnostic differences and challenges in females, the female phenotype, and health and lifespan issues, including vocational services and employment. ASF also invites studies focused on unaffected siblings and recurrence risk in the offspring of unaffected siblings. ASF is also interested in supporting research on the neurobiology and molecular biology of autism using post-mortem brain tissue. The one-year awards include $25,000 for predoctoral and medical students and $35,000 for postdoctoral students.

The Klingenstein Third Generation Foundation ("KTGF") funds programs in children's mental health, principally in the areas of childhood/adolescent depression and ADHD. It also funds medical student programs in child and adolescent psychiatry at select medical institutions. Through these programs, the KTGF seeks to further research in pediatric ADHD and pediatric depression, cultivate more child and adolescent psychiatrists and increase knowledge of mental health in physicians.

Supported by the NIH Common Fund (Common Fund) Science of Behavior Change (SOBC) Program, this Funding Opportunity Announcement (FOA) solicits exploratory and developmental research project applications (R21) that will further the goal of the SOBC Program to advance a mechanisms-focused, experimental medicine approach to behavior change research. Funded projects in the SOBC Research Network have developed experimental manipulations, assays, and/or measures (hereafter referred to as assays for brevity) to support an experimental medicine approach to behavior change research. The SOBC Measures Repository assays are accessible from the SOBC Research Network Open Science Framework (OSF) page at https://osf.io/zp7b4. The goal of this announcement is to leverage SOBC Measures Repository assays of putative targets in self-regulation, stress reactivity and stress resilience, and interpersonal and social processes domains to (1) engage a selected putative target(s)/mechanism(s) of action or verify target engagement of the selected target(s)/mechanism(s) of action, and (2) test the degree to which engaging the putative target(s)/mechanism(s) of action produces a short-term desired change in a health behavior. Putative targets are the mechanisms or processes hypothesized to be malleable and play a causal role in producing behavior change, including medical regimen adherence.

The Office of Refugee Resettlement (ORR) within the Administration for Children and Families (ACF) announces the availability of funds for the fiscal year 2018 Direct Services for Survivors of Torture (DS SOT) grant program. The purpose of the DS SOT program is to increase access to strengths-based, trauma-informed services that assist survivors of torture and their families in the healing and recovery process. Under this grant program, direct services are provided to persons who have been tortured on foreign soil under the color of law. The program offers holistic and integrated services including medical, psychological, legal, and social work. All of these services are provided either directly by the grantee or indirectly through partner organizations or affiliates.